This article has been corrected. Correction in: Oncotarget. 2020; 11:893-893.

Association of PDCD6 polymorphisms with the risk of cancer: Evidence from a meta-analysis

Mohammad Hashemi _, Gholamreza Bahari, Jarosław Markowski, Andrzej Małecki, Marek J. Łos and Saeid Ghavami

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:24857-24868. https://doi.org/10.18632/oncotarget.25324

Metrics: PDF 1360 views  |   HTML 2467 views  |   ?  


Mohammad Hashemi1,2, Gholamreza Bahari2, Jarosław Markowski3, Andrzej Małecki4, Marek J. Łos5,8 and Saeid Ghavami6,7

1Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, Iran

2Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

3ENT Department, School of Medicine, Medical University of Silesia in Katowice, Katowice, Poland

4Faculty of Physiotherapy, The Jerzy Kukuczka Academy of Physical Education in Katowice, Katowice, Poland

5Department of Molecular Biology, School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia in Katowice, Katowice, Poland

6Department of Human Anatomy and Cell Science, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada

7Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran

8Centre de Biophysique Moléculaire, CNRS, Rue Charles Sadron, Orleans, France

Correspondence to:

Mohammad Hashemi, email: [email protected]; [email protected]

Marek J. Łos, email: [email protected]

Keywords: PDCD6; meta-analysis; cancer; risk; endometrial cancer

Received: January 08, 2018     Accepted: April 12, 2018     Published: May 15, 2018


This study was designed to evaluate the relationship between Programmed cell death protein 6 (PDCD6) polymorphisms and cancer susceptibility. The online databases were searched for relevant case-control studies published up to November 2017. Review Manage (RevMan) 5.3 was used to conduct the statistical analysis. The pooled odds ratio (OR) with its 95% confidence interval (CI) was employed to calculate the strength of association. Overall, our results indicate that PDCD6 rs3756712 T>G polymorphism was significantly associated with decreased risk of cancer under codominant (OR = 0.82, 95%CI = 0.70–0.96, p = 0.01, TG vs TT; OR = 0.53, 95%CI = 0.39-0.72, p < 0.0001, GG vs TT), dominant (OR = 0.76, 95%CI = 0.66-0.89, p = 0.0004, TG+GG vs TT), recessive (OR = 0.57, 95%CI = 0.43-0.78, p = 0.0003, GG vs TT+TG), and allele (OR = 0.76, 95%CI = 0.67–0.86, p < 0.00001, G vs T) genetic model. The finding did not support an association between rs4957014 T>G polymorphism of PDCD6, and different cancers risk.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25324